(+/-)-methyl 2-methylene-3-phenylbutanoate | 847654-05-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (+/-)-methyl 2-methylene-3-phenylbutanoate
• 英文别名: methyl 2-methylene-3-phenylbutanoate；Methyl 2-methylidene-3-phenylbutanoate
• CAS: 847654-05-1
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: QHZWUWLGWBJGSD-UHFFFAOYSA-N

物化性质

• 沸点：
  266.6±19.0 °C(Predicted)
• 密度：
  1.015±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+/-)-methyl 2-methylene-3-phenylbutanoate 在 lithium hydroxide monohydrate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 24.0h， 以100%的产率得到2-(1-Phenylethyl)acrylic acid
  参考文献：
  名称：

  Baylis-Hillman 衍生的 SN2' 亲电试剂的镍-铁磷矿催化甲基化机制图

  摘要：

  已经通过计算和实验研究了在亚铁盐配体存在下对 Baylis-Hillman 衍生的烯丙基亲电试剂的对映选择性 Ni 催化甲基化。获得的对映选择性的意义和程度与离去基团和初始烯丙基卤化物的异构结构无关。DFT 研究支持选择性形成有限数量的能量有利的反和顺 π-烯丙基中间体。观察到的区域选择性和对映选择性可以基于这些结构的能量学进行合理化。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)

  DOI：

  10.1002/ejoc.200801029
• 作为产物：
  描述：

  2-(羟基苯基甲基)-丙烯酸甲酯 在 四丁基溴化铵 、 N,N-二甲基甲酰胺 草酰氯 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 3.67h， 生成 (+/-)-methyl 2-methylene-3-phenylbutanoate
  参考文献：
  名称：

  Expedient synthesis of β,β-disubstituted α-methylenepropionates

  摘要：

  Baylis-Hillman alcohols are excellent sources of the allylic halides ArCH=CH(CH2X)(CO2R) (X = Br. Cl: R-1= Me, Et. Bu'). The Z double bond isomers are attained in high isomeric purity (> 14: 1. ZIE). The halides are chemo- and regiospecifically transformed into the acrylates (ArCHR2)C(=CH2)(CO2R1) on treatment with Zn(R-2)(2) (R-2 =Me. Et, CH2TMS, CH(2)SiMe(2)Ome) or PrZnBr- in the presence of catalytic amounts of copper(1) salts (0.5-20 mol%) in high yield. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2004.12.002

文献信息

• TRANSITION METAL COMPLEXES OF AMINO ACIDS AND RELATED LIGANDS AND THEIR USE AS CATALYSTS, ANTI-MICROBIALS, AND ANTI-CANCER AGENTS
  申请人：Virginia Tech Intellectual Properties, Inc.

  公开号：US20130096090A1

  公开（公告）日：2013-04-18

  The present invention relates to the fields of chemistry and pharmaceuticals. Embodiments of the present invention provide transition metal complexes of amino acids. Transition metal complexes of embodiments of the invention according to Categories I, II, III, and/or IV may be used as antimicrobial, anti-malarial, and anti-cancer agents, as well as catalysts in chemical reactions. Such compounds of the invention are particularly useful for combating multi-drug resistance against a broad range of microbials (such as MRSA and mycobacteria), including gram positive and gram negative bacteria, as well as can be used as anti-cancer agents against bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin's lymphoma, pancreatic cancer, prostate cancer, and thyroid cancer, to name a few.

  本发明涉及化学和制药领域。本发明实施例提供了氨基酸的过渡金属配合物。根据本发明的实施例的过渡金属配合物可用作抗微生物、抗疟疾和抗癌剂，以及化学反应中的催化剂。本发明的这类化合物特别适用于对抗广泛范围微生物（如MRSA和分枝杆菌）的多药耐药性，包括革兰氏阳性和革兰氏阴性细菌，也可用作抗癌剂对抗膀胱癌、乳腺癌、结肠癌、直肠癌、子宫内膜癌、肾癌、白血病、肺癌、黑色素瘤、非霍奇金淋巴瘤、胰腺癌、前列腺癌和甲状腺癌等。
• Chiral Palladium(II) Complexes Possessing a Tridentate N‐Heterocyclic Carbene Amidate Alkoxide Ligand: Access to Oxygen‐Bridging Dimer Structures
  作者：Satoshi Sakaguchi、Kyung Soo Yoo、Justin O'Neill、Joo Ho Lee、Timothy Stewart、Kyung Woon Jung

  DOI：10.1002/anie.200803793

  日期：2008.11.17
• Bis-glycinato complexes of palladium(II): Synthesis, structural determination, and hydrogen bonding interactions
  作者：David B. Hobart、Michael A.G. Berg、Joseph S. Merola

  DOI：10.1016/j.ica.2014.07.024

  日期：2014.11

  Palladium(II) acetate and palladium(II) chloride react with glycine and glycine derivatives in acetone/water to yield square planar bis-chelated palladium amino acid complexes. Glycine, N-methylglycine and N,N-dimethylglycine all adopt the trans configuration when prepared from palladium(II) acetate, whereas glycine adopts a cis configuration when prepared from palladium(II) chloride. The crystal structures of all four complexes were obtained. The extended lattice structures arise from N-H center dot center dot O or O center dot center dot(HOH)center dot center dot O hydrogen bonding. Nuclear magnetic resonance, infrared, high resolution mass spectroscopy, and UV-Vis spectroscopic data are evaluated. (C) 2014 Elsevier B.V. All rights reserved.
• US8841281B2
  申请人：——

  公开号：US8841281B2

  公开（公告）日：2014-09-23
• [EN] BORONIC ACID COMPOUND<br/>[FR] COMPOSÉ D'ACIDE BORIQUE<br/>[KO] 보론산 화합물
  申请人：[en]LG CHEM, LTD.;[ko]주식회사 엘지화학

  公开号：WO2022123530A1

  公开（公告）日：2022-06-16

  본 발명은 화학식 1로 표시되는 화합물, 그의 약제학적으로 허용되는 염 또는 이성체, 및 이를 유효성분으로 포함하는 프로테아좀 매개 질환의 치료 또는 예방용 약제학적 조성물에 관한 것이다.